Physician profile
Mark D Sheern
NPI 1083724595
$390.45
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $41.23.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $125.78 | 2019-2020 | |
| Abbvie INC. | $75.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $44.49 | 2019 | |
| Amgen INC. | $39.73 | 2019 | |
| Novo Nordisk INC | $31.14 | 2019-2020 | |
| Vapotherm INC | $29.41 | 2019 | |
| Grifols USA, LLC | $19.21 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.66 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.03 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sheern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.